Title
High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich -2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration.
Document Type
Journal Article
Publisher
Wiley
Faculty
Computing, Health and Science
School
Exercise, Biomedical and Health Science, Centre for Exercise and Sports Science Research
RAS ID
8909
Abstract
Insulin-like growth factor-I (IGF-I) is a known biomarker of recombinant human growth hormone (rhGH) abuse, and is also used clinically to confirm acromegaly. The protein leucine-rich α-2-glycoprotein (LRG) was recently identified as a putative biomarker of rhGH administration. The combination of an ACN depletion method and a 5-min ultra-high-performance liquid chromatography/tandem mass spectrometry (uHPLC/MS/MS)-based selected reaction monitoring (SRM) assay detected both IGF-I and LRG at endogenous concentrations. Four eight-point standard addition curves of IGF-I (16–2000 ng/mL) demonstrated good linearity (r2 = 0.9991 and coefficients of variance (CVs)
DOI
10.1002/rcm.4237
Access Rights
Open access
Comments
Originally published as: Kay, R. G., Barton, C., Velloso, C. P., Brown, P. R., Bartlett, C., Blazevich, A. J., ... & Cowan, D. A. (2009). High‐throughput ultra‐high‐performance liquid chromatography/tandem mass spectrometry quantitation of insulin‐like growth factor‐I and leucine‐rich α‐2‐glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Communications in Mass Spectrometry, 23(19), 3173-3182. Original available here